This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Maurer, M. S. et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N. Engl. J. Med. 389, 1553–1565 (2023)
Related article
Aimo, A. et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat. Rev. Cardiol. 19, 655–667 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fernández-Ruiz, I. Patisiran is beneficial for the treatment of TTR cardiac amyloidosis. Nat Rev Cardiol (2023). https://doi.org/10.1038/s41569-023-00955-2
Published:
DOI: https://doi.org/10.1038/s41569-023-00955-2